Autoinflammatory & rare systemic diseases

Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease

Rheumatology (Oxford)Published Prospective cohort study

Authors' conclusion

Higher Tph2 cells and lower CD19+ B cells in blood and T-B-pathotype in lacrimal glands are potentially associated with increased relapse risk in IgG4-RD.

Study context

Population
Consecutive, active patients with IgG4-related disease (IgG4-RD) at initiation of remission induction therapymedian follow-up 150 weeks
Participants
74 participants
Exposure
Relapse vs non-relapse
  • Relapsen = 19
Outcome
Relapse after remission induction therapy
Methodological detailsconsecutive patients, independent validation cohort, automated image-based quantification of lacrimal gland biopsies
  • Consecutive patients
  • Independent validation cohort
  • Automated image-based quantification of lacrimal gland biopsies

Main finding

As reported in the abstract

Baseline blood immune subsets
GroupValueCD19+ B cells (median, cells/µl)
Relapsemedian 1.8 cells/μl82
Non-relapsemedian 0.9 cells/μl133

Value

Relapsemedian 1.8 cells/μl
Non-relapsemedian 0.9 cells/μl

CD19+ B cells (median, cells/µl)

Relapse82
Non-relapse133
  • Relapse vs Non-relapse: P = 0.018 — higher in relapse
  • Relapse vs Non-relapse: P = 0.002 — lower in relapse
Relapse rate
19 patients (25.7%)

Observational data: associations, not effects.

Further findings

OutcomeP value
Lacrimal gland pathotype and relapseT-B-pathotype vs B-pathotype · higher relapse rate with T-B-pathotypeP = 0.022

Lacrimal gland pathotype and relapse

CX3CR1+ Tph2-like cells accumulated in extrafollicular regions of lacrimal glands with relatively low B cell infiltration (T-B-pathotype)
Findings reproduced in an independent validation set

Original publication

Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease. Rheumatology (Oxford). Published 12 August 2026. doi:10.1093/rheumatology/keag417

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.